The assessment of vegetative and functional symptoms in fibromyalgia patients: The tropisetron experience

Scandinavian Journal of Rheumatology, Supplement

Volumn 33, Issue 119, 2004, Pages 67-71

  Kohnen, R ^a,d   Farber L ^b   Spath M ^c  

^a IMEREM Inst Med Res Mgmt B   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d IMEREM GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TROPISETRON; INDOLE DERIVATIVE; SEROTONIN ANTAGONIST;

AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DYSURIA; FACTORIAL ANALYSIS; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MENTAL DISEASE; MORNING STIFFNESS; NEUROLOGIC DISEASE; PARESTHESIA; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY DISTRESS; SLEEP DISORDER; STOMACH DISEASE; SYMPTOMATOLOGY; TREMOR; XEROSTOMIA; ARTICLE; RANDOMIZED CONTROLLED TRIAL; SICKNESS IMPACT PROFILE;

FIBROMYALGIA; HUMANS; INDOLES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS; SICKNESS IMPACT PROFILE;

EID: 4444358539     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740410007096     Document Type: Conference Paper

References (27)

1. Cohen H, Neumann L, Kotler M, Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Isr Med Assoc J 200 ;3:755-60.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
3. Pongratz DE, Sievers M. Fibromyalgia - symptom or diagnosis? A definition of the position. Scand J Rheumatol 2000;29 Suppl 113:3-7.
4. Muller W, Lautenschlager J. Generalized tendomyopathy. I: Clinical aspects, follow-up and differential diagnosis Z Rheumatol 1990;49:11-21.
5. Conrad I. Diagnosis and clinical signs of fibromyalgia. Schmerz 2003;17:464-74.
6. Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep 2002;6:289-98.
7. Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 2001;13:117-27.
8. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a metaanalytic review. Psychosom Med 2003;65:528-33.
9. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003;7:362-8.
10. Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000;2:116-23.
11. Bruckle W, Lautenschlager J, Muller W. The course and topography of pain in generalized tendomyopathies. Z Rheumatol 1991;50 Suppl 1:19-28.
12. Samborski W, Stratz T, Sobieska M, Mennet P, Muller W. Pressure point studies in generalized tendomyopathy (fibromyalgia) (comparison of various methods). Z Rheumatol 1991;50:382-6.
13. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-13.
14. Petzke F, Khine A, Williams D, Groner R, Clauw DJ, Gracely RH. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 2001;28:2568-9.
15. Lautenschlager J, Seglias J, Bruckle W, Muller W. Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol 1991;10:168-73.
16. Samborski W, Stratz T, Kretzmann WM, Mennet P, Muller W. Comparative studies of the incidence of vegetative and functional disorders in backache and generalized tendomyopathies. Z Rheumatol 1991;50:378-81.
17. Muller W, Lautenschlager J. Generalized tendomyopathy. I: Clinical aspects, follow-up and differential diagnosis. Z Rheumatol 1990;49:11-21.
18. Farber L, Stratz T, Bruckle W, Spath M, Pongratz D, Lautenschlager J, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol 2000;29 Suppl 113:49-54.
19. von Zerssen D. Die Beschwerde-Liste. Weinheim: Beltz 1976.
20. Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A "blinded," controlled study of symptoms and tender points. Arthritis Rheum 1983;26:817-24.
21. Haus U, Varga B, Stratz T, Spath M, Muller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000;29 Suppl 113:55-58.
22. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000;29 Suppl 113:59-62.
23. Rau CL, Russell IJ. Is fibromyalgia a distinct clinical syndrome? Curr Rev Pain 2000;4:287-94.
24. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000;27:2660-5.
25. Lapossy E, Gasser P, Hrycaj P, Dubler B, Samborski W, Muller W. Cold-induced vasospasm in patients with fibromyalgia and chronic low back pain in comparison to healthy subjects. Clin Rheumatol 1994;13:442-5.
26. Burckhardt CS, O'Reilly CA, Wiens AN, Clark SR, Campbell SM, Bennett RM. Assessing depression in fibromyalgia patients. Arthritis Care Res 1994;7:35-9.
27. Winfield JB. Psychological determinants of fibromyalgia and related syndromes. Curr Rev Pain 2000;4:276-86.